Almost one in five patients with melanoma do not receive the support of a skin cancer specialist nurse, a snapshot survey by charity Melanoma Focus has found.
2022
Adjuvant Nivolumab/Ipilimumab vs Nivolumab in Resected Stage IIIB–D or IV Melanoma
As reported in the Journal of Clinical Oncology by Jeffrey S. Weber, MD, PhD, and colleagues, the phase III CheckMate 915 trial showed no improvement in recurrence-free survival with adjuvant nivolumab/ipilimumab vs nivolumab in patients with resected stage IIIB–D or IV melanoma.
‘Negligible’ melanoma risk observed in patients treated with methotrexate
Findings from a comprehensive systematic review and meta-analysis showed a “negligible” risk for melanoma among individuals treated with methotrexate.
Who is Getting a Skin Cancer Screening?
Authors of an oral abstract at the 2022 ASDS Annual Meeting presented their findings on the demographics of who requests total body skin exams to screen for skin cancer.